Clinical Trial Scheme of Tanreqing Capsules in the Treatment of COVID-19

Status Completed

Clinical Trial Summary

This study was conducted in a randomized, double-blind, placebo-controlled, multicenter clinical trial design. Two groups were designed, the experimental group and the placebo control group. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit.

Clinical Trial Description

The purpose of this study was to evaluate the efficacy and safety of Tanreqing capsule in the treatment of mild and common COVID-19. The trial was a randomized, double-blind, placebo-controlled, multicenter clinical trial design. A total of 480 patients were divided into 2 groups: experimental group and control group 3:1. Patients in both groups received basic treatment with vitamin C effervescent tablets. Tanreqing capsule was added to basic treatment in the experimental group, and placebo was added to basic treatment in the control group. The treatment course was 7 days, and the observation period was set to 7 days, with a daily visit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05305456
Study type	Interventional
Source	Jiangsu Famous Medical Technology Co., Ltd.
Contact
Status	Completed
Phase	Phase 3
Start date	March 28, 2022
Completion date	August 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04798716` - The Use of Exosomes for the Treatment of Acute Respiratory Distress Syndrome or Novel Coronavirus Pneumonia Caused by COVID-19	Phase 1/Phase 2
Recruiting	`NCT04314271` - The Observational Study of Cardiac and Pulmonary Ultrasound and Evaluation of Treatment of Severe Patients With Novel Coronavirus Pneumonia
Recruiting	`NCT04282902` - A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection	Phase 3
Withdrawn	`NCT04285190` - The Effect of T89 on Improving Oxygen Saturation and Clinical Symptoms in Patients With COVID-19	N/A
Recruiting	`NCT04283396` - Study for Novel Coronavirus Pneumonia (NCP)
Active, not recruiting	`NCT04273763` - Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19)	N/A
Completed	`NCT04280224` - NK Cells Treatment for COVID-19	Phase 1
Completed	`NCT04273321` - Efficacy and Safety of Corticosteroids in COVID-19	N/A
Enrolling by invitation	`NCT04365309` - Protective Effect of Aspirin on COVID-19 Patients	Phase 2/Phase 3
Completed	`NCT04645407` - Effects of Fuzheng Huayu Tablets on COVID-19	Phase 4